Colinz Laboratories Limited carries a market capitalization of 167.52M, placing it among publicly traded companies globally. Its enterprise value stands at 135.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 167.52M |
| Enterprise Value | 135.48M |
Colinz Laboratories Limited trades at a trailing price-to-earnings ratio of 27.44.
| PE Ratio | 27.44 |
| PS Ratio | 2.32 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, Colinz Laboratories Limited trades at an EV/EBITDA multiple of 51.49 and an EV/FCF ratio of 314.18. The EV/Sales ratio of 2.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 51.49 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.32 |
| EV / EBITDA | 51.49 |
| EV / EBIT | 51.49 |
| EV / FCF | 314.18 |
Colinz Laboratories Limited maintains a current ratio of 8.67, meaning it holds 8.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.46, indicating elevated leverage, while an interest coverage ratio of 5.05 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 8.67 |
| Quick Ratio | 6.19 |
| Debt / Equity | 13.46 |
| Debt / EBITDA | N/A |
| Interest Coverage | 5.05 |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 14.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Over the trailing twelve months, Colinz Laboratories Limited has paid 1.03M in income taxes, reflecting an effective tax rate of 17.23.
| Income Tax | 1.03M |
| Effective Tax Rate | 17.23 |
Colinz Laboratories Limited's stock has gained approximately 68.69609% over the past 52 weeks. The 50-day moving average sits at 56.97, while the 200-day moving average is 49.57.
| Beta (5Y) | N/A |
| 52-Week Price Change | 68.69609% |
| 50-Day Moving Average | 56.97 |
| 200-Day Moving Average | 49.57 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Colinz Laboratories Limited generated 58.40M in revenue and converted that into 4.94M in net income, yielding earnings per share of 1.95. EBITDA reached 2.63M, while operating income came in at 2.63M.
| Revenue | 58.40M |
| Gross Profit | 42.06M |
| Operating Income | 2.63M |
| Pretax Income | 5.97M |
| Net Income | 4.94M |
| EBITDA | 2.63M |
| EBIT | 2.63M |
| Earnings Per Share (EPS) | 1.95 |
Colinz Laboratories Limited operates with a gross margin of 72.02, reflecting its pricing power and cost economics. The operating margin of 4.51 and net profit margin of 8.45 provide insight into operational efficiency.
| Gross Margin | 72.02 |
| Operating Margin | 4.51 |
| Pretax Margin | 10.21 |
| Profit Margin | 8.45 |
| EBITDA Margin | 4.51 |
Colinz Laboratories Limited posts an Altman Z-Score of 5.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.37 |